Barcelona, April 11, 2014. Preclinical, translational and clinical researchers and physician-scientists from the Vall d’Hebron Institute of Oncology (VHIO) attended…
Search Results ""
Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.
PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected José Baselga, M.D., Ph.D., physician-in-chief at Memorial Sloan Kettering Cancer Center in New York, N.Y., as their president-elect for 2014-2015. Baselga is an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents for the treatment of cancer, particularly breast cancer.
An international study published in The New England Journal of Medicine, in which the Vall d’Hebron University Hospital and Vall d´Hebron Institute of Oncology (VHIO) have participated, shows that administering bevacizumab in combination with chemotherapy in the first-line treatment of patients with recurrent and/or metastatic cervical cancer improves survival rates and reduces risk of death from this disease by 30%.
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
An interview with Ana Vivancos, Principal Investigator of VHIO´s Cancer Genomics Group “We are one of the few groups in…
Molecular Oncology 8 (2014) 1-8 News and views Towards individualized cancer therapy: Challenges and prospects Ezzie Hutchinson ABSTRACT At the…
Taking place on Monday 24 February 2014, 09:15 – 10:30, at the Hotel Alimara Barcelona, we are delighted to announce…
4th February, 2014, Strasbourg, France. A unique group of patient advocacy organisations, healthcare leaders (including two former health ministers and…
